Drug Database
FR

Fraction F (Fraction F / Ateroid / Ateroid 200)

✓ Approved

Gentium · therapeutic agent

What is Fraction F?

Fraction F is a therapeutic agent developed by Gentium. It is approved for therapeutic indications via injectable (others) or intravenous (iv) or oral (po).

Drug Profile

Brand NamesFraction F, Ateroid, Ateroid 200
CompanyGentium
RouteInjectable (Others), Intravenous (IV), Oral (PO)
StatusApproved

Therapeutic Indications

Fraction F is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Nervous system disordersDementia Alzheimer's type✓ Approved

Related Research Articles

PubMedFrontiers in psychology2026-10-15

Effects of psychological skills training on self-control, perceived physical self-defense capacity, and mental toughness in elite female wrestlers: a randomized controlled trial.

Tutal Varol V, Demir Okan O, Şahin Oktay O, Albayrak Ahmet Yılmaz AY et al.

Self-control, self-defense self-efficacy, and mental resilience are fundamental psychological determinants of performance and competitive endurance in combat sports. However, scientific evidence on structured, evidence-based psychological intervention programs for professional female wrestlers remains limited. This study examined the effects of a psychological skills training (PST)-based intervention on self-control, self-defense self-efficacy, and mental resilience in professional female wrestlers. A randomized controlled pre-test-post-test design was employed. Thirty-six professional female wrestlers (aged 18-25) were randomly assigned to a PST group (n = 18) or a control group (CG; n = 18). The PST group completed an 8-week structured psychological intervention alongside regular training, while the CG continued routine training only. Self-control, self-defense self-efficacy, and mental resilience were assessed pre- and post-intervention using valid and reliable psychometric scales. Data were analyzed via repeated-measures ANOVA, with effect sizes calculated. Significant group × time interactions were observed across multiple outcomes. A highly significant interaction emerged for perceived physical self-defense capacity (SP; F(1,34) = 56.525, p < 0.001, ηp2 = 0.624) and for DP scores (F (1,34) = 9.360, p = 0.004, ηp2 = 0.216). Among self-control subscales, significant interactions were found for inhibition (F (1,34) = 8.172, p = 0.007, ηp2 = 0.194) and, more strongly, for initiation (F (1,34) = 14.157, p < 0.001, ηp2 = 0.294). For mental resilience, highly significant interactions were detected for confidence (F (1,34) = 59.976, p < 0.001, ηp2 = 0.638), control (F (1,34) = 32.486, p < 0.001, ηp2 = 0.489), and persistence (F (1,34) = 32.709, p < 0.001, ηp2 = 0.490). Overall, the intervention demonstrated medium-to-high effect sizes across psychological performance indicators. These findings suggest that PST may serve as a useful complementary approach for enhancing self-control, perceived physical self-defense capacity, and mental toughness in professional female wrestlers. However, results should not be interpreted as evidence of improved competitive wrestling performance, technical success, or objectively measured physical self-defense ability, as these outcomes were not directly assessed in this study.

PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-10-15

Development of Versatile Nanoparticle System for Efficient Drug Delivery into Pulmonary Endothelium.

Mohammed Afzaal N AN, Deng Zicheng Z, Misra Arnab A, Orzabal Marcus M et al.

Drug delivery precisely to the pulmonary vasculature represents a formidable challenge. Pediatric Acute Respiratory Distress Syndrome (PARDS) is an urgent public health concern accounting for high mortality and long-term morbidity due to severe damage to lung endothelial cells (ECs). Advanced target-specific therapeutic interventions to protect lung vasculature in PARDS are in dire need. FOXF1 protein is a critical mediator of lung angiogenesis and vascular repair after injury. However, whether FOXF1 is a useful pharmacological target for PARDS is unknown. Herein, we developed a universal nanoparticle-based Lung Endothelial Drug Delivery (LEDD) system to deliver hydrophobic small-molecule compounds specifically to lung ECs but not to other cells or organs. Based on single-cell RNA sequencing, FOXF1 expression was decreased in lung ECs in the mouse PARDS model. We used LEDD nanoparticles to restore FOXF1 by delivering a novel FOXF1-activating compound, TanFe[F], which prevents FOXF1 protein degradation. LEDD-TanFe[F] treatment increased FOXF1 protein and its activity in lung ECs in vitro and in vivo. LEDD-TanFe[F] treatment was non-toxic, well-tolerated, and improved mice survival in the PARDS model. LEDD-TanFe[F] reduced endothelial permeability, improved vascular repair, and alveolarization in injured neonatal lungs. LEDD-supported drug delivery precisely to lung ECs is a promising therapeutic approach in PARDS.

PubMedFrontiers in nutrition2026-10-15

Impact of a 12-week high-intensity interval training program on working memory in young adults with overweight or obesity.

Zhu Li-Na LN, Yuan Wei W, Gu Qi-Zheng QZ, Yang Qi-Ling QL et al.

To examine the association of a 12-week high-intensity interval training (HIIT) program with working-memory performance in young adults aged 18-25 years with overweight or obesity. A total of 120 young adults with overweight or obesity were randomly allocated to an HIIT group (n = 48) or a control group (n = 72). The HIIT group completed a 12-week structured program, whereas the control group maintained usual daily activities. Working-memory updating was assessed using 1-back and 2-back tasks. Post-test body weight and maximal oxygen consumption (VO2max) were analysed using baseline-adjusted analysis of covariance (ANCOVA), whereas body mass index (BMI) was analysed using repeated-measures ANCOVA. Reaction-time outcomes were analysed using a 2 × 2 × 2 mixed repeated-measures ANCOVA, with group as the between-subject factor and time and cognitive load as within-subject factors. Because marked baseline imbalance was observed for accuracy, 1-back and 2-back accuracy were analysed separately using baseline-adjusted post-test ANCOVA. Exploratory partial correlation analyses examined associations between changes in VO2max and n-back performance separately within the HIIT and control groups. An additional exploratory linear regression model tested whether the association between VO2max improvement and 2-back reaction-time improvement differed between groups. Baseline-adjusted ANCOVA showed lower post-test body weight in the HIIT group than in the control group [F(1,115) = 110.07, p < 0.001, η2 = 0.256] and higher post-test VO2max [F(1,115) = 300.86, p < 0.001, η2 = 0.451]. Repeated-measures ANCOVA showed a significant group × time interaction for BMI [F(1,115) = 137.60, p < 0.001, η2 = 0.545]. For reaction time, the 2 × 2 × 2 mixed repeated-measures ANCOVA showed a significant group × time interaction [F(1,115) = 31.95, p < 0.001, partial η2 = 0.217] and a significant group × cognitive-load interaction [F(1,115) = 9.22, p = 0.003, partial η2 = 0.074], whereas the group × time × cognitive-load interaction was not significant [F(1,115) = 2.15, p = 0.145, partial η2 = 0.018]. After adjustment for baseline accuracy and other measured baseline covariates, no significant post-test group difference was observed in 1-back accuracy [F(1,114) = 0.91, p = 0.343] or 2-back accuracy [F(1,114) = 2.17, p = 0.143]. In exploratory analyses, VO2max improvement was associated with 2-back reaction-time improvement in the HIIT group (r = 0.391, p = 0.009) but not in the control group (r = -0.101, p = 0.411). However, the group × VO2max-improvement interaction did not reach conventional statistical significance (β = 388.57, 95% CI: -7.68 to 784.82, p = 0.055). Participation in the 12-week HIIT program was associated with lower adjusted post-test body weight, higher adjusted post-test VO2max, a greater reduction in BMI, and more favorable reaction-time performance averaged across n-back loads. No adjusted post-test between-group difference in accuracy was observed. The non-significant group × time × cognitive-load interaction does not support a cognitive-load-specific effect. Although the VO2max-2-back reaction-time association was observed in the HIIT group but not in the control group, the non-significant interaction model did not conclusively establish training specificity. Dietary intake, habitual physical activity, sedentary behavior, complete individual-level exercise intensity, and formal assessor blinding were not available; therefore, the observed differences cannot be attributed exclusively to HIIT.

PubMedJournal of magnetic resonance imaging : JMRI2026-10-15

Editorial for "Association of Cardiac MRI-Derived Epicardial Adipose Tissue Index With Adverse Clinical Outcomes in Heart Failure With Preserved Ejection Fraction".

Jia Han H, Zhu Yinsu Y

PubMedFrontiers in pharmacology2026-10-15

Handling missed dose of riluzole by population pharmacokinetic model informed remedial regimen.

Liu Changlong C, Tang Qing Q, Yu Lingyan L, Yu Zhenwei Z

Patients with amyotrophic lateral sclerosis (ALS) frequently exhibit nonadherence characterized by delayed or missed doses while taking riluzole. This study aimed to provide a population pharmacokinetic (PPK) model informed individualized remedial regimens for patients who experience delayed or missed doses of riluzole. A PPK model for riluzole was developed via a nonlinear mixed-effect modeling approach based on 3,024 concentration-time points from 72 subjects. The final model was validated by multiple methods. Six remedial regimens for missed doses were simulated for concentration-time profiles under different scenarios, and the optimal remedial regimen was selected based on the least time of concentration beyond the normal range. The PPK model of riluzole was best described with a two-compartment model with body weight as a covariate of peripheral distribution volume. The typical values of CL/F, Vc/F, Vp/F and Q were 67 L/h, 242 L, 376 L and 33.1 L/h, respectively. The model was showed acceptable performance by goodness-of-fit, visual predictive check, bootstrap analysis and normalized distribution prediction errors. Model-based remedial regimens for different missed scenarios were proposed. A riluzole PPK model was developed and internally evaluated using multiple diagnostic approaches. Model-based remedial dosing strategies for different missed-dose scenarios were identified based on predefined PK criteria and Monte Carlo simulations. These exploratory strategies provide quantitative insights into riluzole exposure during nonadherent dosing conditions.

PubMedNature communications2026-10-15

Multimodal data-driven clustering analysis of heart failure patients identifies two distinct patterns of heart failure with preserved ejection fraction: Results from the PACIFIC-PRESERVED study.

Hulot Jean-Sébastien JS, Hervé Pierre-Yves PY, Girerd Nicolas N, Chézalviel-Guilbert Frédérique F et al.

Heart failure with preserved ejection fraction (HFpEF) accounts for over half of heart failure cases but remains poorly defined due to its clinical heterogeneity. In the prospective PACIFIC-Preserved cohort (NCT04189029, n = 155), we applied multimodal deep phenotyping, including high-throughput proteomics, and unsupervised machine learning to identify biologically distinct HFpEF subgroups. Multiview clustering revealed two major HFpEF phenogroups: PEF1, characterized by inflammatory signaling, TNF receptor activation, cardio-skeletal injury, and greater renal dysfunction; and PEF2, marked by endothelial stress and milder perturbations. Conventional diagnostics alone could not reliably distinguish these subgroups, but a multimodal classifier integrating clinical, imaging, and proteomic variables achieved high predictive accuracy (F1-score 0.87). External validation in the MEDIA-DHF cohort (n = 456) confirmed that PEF1 was independently associated with adverse outcomes (adjusted HR 2.27, 95% CI 1.04-4.94). These findings establish a classifier-driven, biologically informed stratification of HFpEF, providing a framework for precision medicine in heart failure.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Fraction F